Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REPLIGEN CORPORATION

(RGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Repligen Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

10/28/2021 | 04:51pm EST

Repligen Corporation reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 178.22 million compared to USD 94.06 million a year ago. Net income was USD 33.5 million compared to USD 14.55 million a year ago. Basic earnings per share from continuing operations was USD 0.61 compared to USD 0.28 a year ago. Diluted earnings per share from continuing operations was USD 0.58 compared to USD 0.27 a year ago. For the nine months, revenue was USD 484.01 million compared to USD 257.61 million a year ago. Net income was USD 99.18 million compared to USD 40.23 million a year ago. Basic earnings per share from continuing operations was USD 1.81 compared to USD 0.77 a year ago. Diluted earnings per share from continuing operations was USD 1.74 compared to USD 0.75 a year ago.


ę S&P Capital IQ 2021
All news about REPLIGEN CORPORATION
01/12Repligen Seeks Acquisitions
CI
01/04REPLIGEN CORP : Change in Directors or Principal Officers, Financial Statements and Exhibi..
AQ
01/04Repligen Corporation Promotes James Bylund to the Chief Operating Officer and Principal..
CI
2021Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference
AQ
2021REPLIGEN CORP : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ..
AQ
2021Repligen Corporation acquired Bio-Flex Solutions, L.L.C. / Newton T & M Corp.
CI
2021INSIDER SELL : Repligen
MT
2021INSIDER SELL : Repligen
MT
2021Repligen Corporation to Present at Upcoming Investor Conferences
GL
2021Repligen Releases Inaugural Sustainability Report
AQ
More news
Analyst Recommendations on REPLIGEN CORPORATION
More recommendations
Financials (USD)
Sales 2021 664 M - -
Net income 2021 128 M - -
Net cash 2021 431 M - -
P/E ratio 2021 82,0x
Yield 2021 -
Capitalization 10 163 M 10 163 M -
EV / Sales 2021 14,6x
EV / Sales 2022 11,9x
Nbr of Employees -
Free-Float -
Chart REPLIGEN CORPORATION
Duration : Period :
Repligen Corporation Technical Analysis Chart | RGEN | US7599161095 | MarketScreener
Technical analysis trends REPLIGEN CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 183,81 $
Average target price 321,63 $
Spread / Average Target 75,0%
EPS Revisions
Managers and Directors
Tony J. Hunt President, Chief Executive Officer & Director
Jon K. Snodgres Chief Financial Officer
Karen A. Dawes Chairman
Ralf Kuriyel Senior Vice President-Research & Development
James R. Bylund Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
REPLIGEN CORPORATION-28.84%10 163
ABBOTT LABORATORIES-10.59%215 794
MEDTRONIC PLC2.57%141 985
BECTON, DICKINSON AND COMPANY5.23%75 431
HOYA CORPORATION-11.34%49 186
BAXTER INTERNATIONAL INC.0.51%43 200